Form 4: Camp4 Therapeutics CEO Converts Preferred Stock to Common Stock Following IPO

CEO Josh Mandel-Brehm converted Series B Preferred Stock to Common Stock following Camp4 Therapeutics' initial public offering.

Summary

• On October 15, 2024, Josh Mandel-Brehm, CEO of Camp4 Therapeutics, converted 6,791 shares of Series B Convertible Preferred Stock into 605 shares of Common Stock.
• This conversion occurred automatically upon the closing of Camp4 Therapeutics' initial public offering (IPO).
• The conversion ratio was 11.2158-for-one, meaning each share of Series B Preferred Stock converted into 11.2158 shares of Common Stock.
• Following the transaction, Mandel-Brehm directly owns 272,357 shares of Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction following the IPO, indicating a neutral to slightly positive sentiment as it signifies the completion of a major milestone.

Positives

• The conversion of preferred stock to common stock typically signals increased confidence in the company's future prospects following its IPO.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are standard practice after significant events like IPOs, providing transparency into insider transactions and ownership changes.

Stakeholder Impact

• The conversion of preferred stock to common stock may have a minor impact on shareholders due to the change in the capital structure.

Key Dates